Phenylalanine supplementation in Tyrosinemia type 1

The effect of phenylalanine supplementation on metabolic control in Tyrosinemia type 1 patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON23208

Enrollment

Registered

2018-06-08

Start date

2017-02-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tyrosinemia type 1 phenylalanine supplementation tyrosine

Interventions

Different doses of phenylalanine supplementation will be given during some days. The effect of the supplementation on metabolic control will be studied while receiving the different dosages.

Eligibility

Inclusion criteria

Inclusion criteria: - Diagnosed with Tyrosinemia type 1 - Treated with NTBC - Adequate dietary control (tyrosine concentrations: 200-600 µmol/L)

Exclusion criteria

Exclusion criteria: - Tyrosinemia type 1 patients who received liver transplantation

Design outcomes

Primary

Measure	Time frame
Blood phenylalanine concentrations Blood tyrosine concentrations	—

Secondary

Measure	Time frame
Blood NTBC concentrations Blood succinylacetone concentrations	—

Contacts

Public ContactF.J. van Spronsen

f.j.van.spronsen@umcg.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)